Brief: Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial
18/12/2025 13:33
Dec 18 (Reuters) - Actinogen Medical Ltd ACW.AX: FINAL, 247TH PARTICIPANT RANDOMIZED AND COMMENCES TREATMENT IN ACTINOGEN’S XANAMIA PIVOTAL PHASE 2B/3 ALZHEIMER’S TRIAL ACTINOGEN MEDICAL LTD - TOPLINE FINAL RESULTS FOR XANAMIA TRIAL IN NOVEMBER 2026 Source text: ID:nGNX310h1n Further company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinogen Medical
See all newsBrief: Actinogen Commences Open-Label Phase Of Xanamia Alzheimer’S Trial And Provides Business Update
Brief: Actinogen Medical Completes A$16.8M Placement And Spp
Brief: Actinogen Medical To Raise A$12.0 Million
Brief: Actinogen Medical Seeks Trading Halt
Brief: Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial